Table 2.
Number of study participants reporting symptoms and corresponding symptom durations
|
People with tuberculosis (N=80) |
People with COVID-19 (N=212) |
People with tuberculosis with concurrent positive Xpert Xpress test (N=13) |
||||
|---|---|---|---|---|---|---|
| Participants reporting symptoms | Symptom duration, days | Participants reporting symptoms | Symptom duration, days | Participants reporting symptoms | Symptom duration, days | |
| Breathing difficulties | 36 (45%) | 10 (4–15) | 91 (43%) | 3 (2–4) | 7 (54%) | 7 (6–15) |
| Cough | 76 (95%) | 20 (10–37) | 199 (94%) | 5 (3–8) | 12 (92%) | 15 (7–24) |
| Cough less than 2 weeks | 24 (30%) | 7 (5–9) | 176 (83%) | 5 (3–7) | 5 (39%) | 7 (4–7) |
| Cough 2 weeks or longer | 52 (65%) | 32 (20–52) | 23 (11%) | 20 (15–33) | 7 (54%) | 20 (17–42) |
| Fatigue | 56 (70%) | 14 (7–19) | 162 (76%) | 4 (3–7) | 9 (69%) | 7 (5–15) |
| Fever | 55 (69%) | 5 (3–14) | 141 (67%) | 2 (2–4) | 7 (54%) | 3 (2–10) |
| General malaise | 65 (81%) | 12 (6–18) | 187 (88%) | 4 (3–7) | 11 (85%) | 7 (5–15) |
| Headache | 58 (73%) | 10 (5–15) | 188 (89%) | 4 (3–6) | 9 (69%) | 13 (6–15) |
| Loss of smell | 7 (9%) | 7 (6–11) | 66 (31%) | 3 (2–5) | 2 (15%) | 5 (4–6) |
| Loss of taste | 8 (10%) | 6 (5–9) | 56 (26%) | 3 (2–5) | 1 (8%) | 3 (3–3) |
| Muscle pain | 59 (74%) | 10 (7–15) | 169 (80%) | 4 (3–7) | 8 (62%) | 7 (5–15) |
| Sore throat | 72 (90%) | 15 (7–33) | 184 (87%) | 4 (3–7) | 12 (92%) | 7 (6–9) |
| Thoracic pain | 60 (75%) | 14 (7–25) | 135 (64%) | 4 (3–6) | 11 (85%) | 7 (7–16) |
Data are n (%) or median (IQR). Data stratified by disease diagnosis in 80 people with tuberculosis, as defined by culture-positivity; in 212 people with COVID-19, as defined by a positive result on Xpert Xpress with nasopharyngeal swab; and in 13 people with culture-positive tuberculosis and a concurrently positive Xpert Xpress test (nasopharyngeal swab or sputum).